Retrospective evaluation of response to epoetin alfa in patients with hematologic disorders

Journal of Oncology Pharmacy Practice

Volumn 10, Issue 1, 2004, Pages 1-6

  Kolesar, Jill M ^a   Duren, Betsy A ^b   Baranski, Bruce G ^b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Epoetin alfa; Hematological malignancies; Myelodysplasia

Indexed keywords

ANTINEOPLASTIC AGENT; CREATININE; ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; ERYTHROCYTE CONCENTRATE; FEMALE; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN DETERMINATION; HOSPITAL PATIENT; HUMAN; MALE; MEDICAL RECORD; MYELODYSPLASIA; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STUDENT T TEST;

EID: 1542502830     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155204jp117oa     Document Type: Article

References (9)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1996; 91: 1616-34.
2. Ludwig H. Anemia of hematologic malignancies: What are the treatment options? Semin Oncol 2002; 29 (Suppl 8): 45-54.
3. Demetri GD, Kris M, Wade J, Degros L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16: 3412-25.
4. Oliva EN, D;Angelo A, Martino B, Nobile F, Dimitrov BD, Perna A. More concern about transfusion requirement when evaluating quality of life in anemic patients. J Clin Oncol 2002; 20: 3182-83; discussion 3183-84.
5. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djullbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. American Society of Clinical Oncology. American Society of Hematology. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20: 4083-107.
6. Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, Gordon MS, Lichtin AE, Wade JL III, Woolf S, Aronson N. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 93: 1204-14.
7. Quirt I, Roberson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S, Tang SC, McKenzie M, Couture F. Canadian Eprex Oncology Study Group. Epoetin alfa therapy increases Hb levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001; 19: 4126-34.
8. Vansteenskiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J. Aranesp 980297 Study Group. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94: 1211-20.
9. Anonymous. Arandomized double-blind placebo controlled study with subcutaneous recombinant human erythropoietin in patients with low risk myelodysplastic syndromes: Italian Cooperative Group study for rHUEpo in Myelodysplastic Syndromes. Br J Hematol 1998; 103: 1070-74.